We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multiparameter System Featuring Wearable Biosensor Enables Near Real-Time Patient Monitoring

By HospiMedica International staff writers
Posted on 03 Dec 2024

A novel cloud-based system featuring a wearable biosensor with chest-based SpO2 monitoring enables continuous patient monitoring across both hospital and out-of-hospital care settings. More...

The UbiqVue 2A Multiparameter System, developed by LifeSignals (Milpitas, CA, USA), represents a significant advancement in wireless, continuous patient monitoring for population health management. This system can be used in home, remote, and hospital environments to monitor patients’ physiological data in real time, improving patient safety and replacing traditional spot-check methods that can be labor-intensive and prone to inaccuracies. At the core of this system is the UbiqVue 2A Biosensor, a single-use, all-in-one wearable device designed to continuously collect SpO2 data from the chest. It also tracks a total of 12 other vital parameters, including 2-channel ECG, pulse rate, PPG, respiration rate, body temperature, and motion.

The data collected by the biosensor is encrypted and transmitted securely in near real-time via a relay app or access point to a secure cloud system, where it undergoes signal processing. Healthcare professionals and caregivers can access this continuous stream of vital signs from anywhere through the UbiqVue web portal and receive alert notifications. Designed to integrate seamlessly into clinical workflows, UbiqVue offers scalability across healthcare systems. Following its FDA Class II 510(k) clearance, the UbiqVue 2A Multiparameter System is set to revolutionize both individualized patient care and broader population health strategies.

"This FDA 510(k) approval marks a major milestone in LifeSignals' mission to deliver bedside patient monitor-like functionality through an affordable, single-use disposable Biosensor, enabling population health management," said Surendar Magar, Co-founder and CEO. "It shows our commitment to the vision of expanding the UbiqVue system with additional vital signs and advanced AI capabilities. Through global partnerships with OEMs, service providers, IDTFs, and distributors, we aim to transform healthcare at scale."

Related Links:
LifeSignals


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Immobilization System
Cranial 4Pi Immobilization
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.